Development and validation of a prediction model for invasive bacterial infections in febrile children at European Emergency Departments: MOFICHE, a prospective observational study.


Journal

Archives of disease in childhood
ISSN: 1468-2044
Titre abrégé: Arch Dis Child
Pays: England
ID NLM: 0372434

Informations de publication

Date de publication:
07 2021
Historique:
received: 22 07 2020
revised: 25 10 2020
accepted: 27 10 2020
pubmed: 20 11 2020
medline: 14 9 2021
entrez: 19 11 2020
Statut: ppublish

Résumé

To develop and cross-validate a multivariable clinical prediction model to identify invasive bacterial infections (IBI) and to identify patient groups who might benefit from new biomarkers. Prospective observational study. 12 emergency departments (EDs) in 8 European countries. Febrile children aged 0-18 years. IBI, defined as bacteraemia, meningitis and bone/joint infection. We derived and cross-validated a model for IBI using variables from the Feverkidstool (clinical symptoms, C reactive protein), neurological signs, non-blanching rash and comorbidity. We assessed discrimination (area under the receiver operating curve) and diagnostic performance at different risk thresholds for IBI: sensitivity, specificity, negative and positive likelihood ratios (LRs). Of 16 268 patients, 135 (0.8%) had an IBI. The discriminative ability of the model was 0.84 (95% CI 0.81 to 0.88) and 0.78 (95% CI 0.74 to 0.82) in pooled cross-validations. The model performed well for the rule-out threshold of 0.1% (sensitivity 0.97 (95% CI 0.93 to 0.99), negative LR 0.1 (95% CI 0.0 to 0.2) and for the rule-in threshold of 2.0% (specificity 0.94 (95% CI 0.94 to 0.95), positive LR 8.4 (95% CI 6.9 to 10.0)). The intermediate thresholds of 0.1%-2.0% performed poorly (ranges: sensitivity 0.59-0.93, negative LR 0.14-0.57, specificity 0.52-0.88, positive LR 1.9-4.8) and comprised 9784 patients (60%). The rule-out threshold of this model has potential to reduce antibiotic treatment while the rule-in threshold could be used to target treatment in febrile children at the ED. In more than half of patients at intermediate risk, sensitive biomarkers could improve identification of IBI and potentially reduce unnecessary antibiotic prescriptions.

Identifiants

pubmed: 33208397
pii: archdischild-2020-319794
doi: 10.1136/archdischild-2020-319794
pmc: PMC8237171
doi:

Substances chimiques

Anti-Bacterial Agents 0
Biomarkers 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

641-647

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Hum Vaccin Immunother. 2019;15(2):459-469
pubmed: 30273506
BMJ. 2010 Apr 20;340:c1594
pubmed: 20406860
JAMA. 2016 Aug 23-30;316(8):835-45
pubmed: 27552617
J Clin Epidemiol. 2016 Jan;69:245-7
pubmed: 25981519
Pediatrics. 2017 Aug;140(2):
pubmed: 28679639
Pediatrics. 2014 Jun;133(6):e1647-54
pubmed: 24819580
Sci Rep. 2019 Aug 13;9(1):11780
pubmed: 31409879
PLoS Med. 2020 Aug 19;17(8):e1003208
pubmed: 32813708
Stat Methods Med Res. 2018 Jan;27(1):185-197
pubmed: 27460537
Arch Dis Child. 2018 Nov;103(11):1033-1041
pubmed: 29794106
PLoS Med. 2020 Jan 31;17(1):e1003034
pubmed: 32004317
Stat Med. 2004 Aug 30;23(16):2567-86
pubmed: 15287085
BMJ. 2013 Apr 02;346:f1706
pubmed: 23550046
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Lancet Infect Dis. 2017 Apr;17(4):431-440
pubmed: 28012942
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
Lancet. 2019 Aug 31;394(10200):757-779
pubmed: 31257127
Pediatrics. 2016 Aug;138(2):
pubmed: 27382134
PLoS One. 2015 Mar 18;10(3):e0120012
pubmed: 25785720
BMJ. 2011 Mar 08;342:d1277
pubmed: 21385800
J Clin Epidemiol. 2016 Jun;74:167-76
pubmed: 26772608
BMJ Paediatr Open. 2019 Jun 27;3(1):e000456
pubmed: 31338429
Pediatr Infect Dis J. 2018 May;37(5):387-393
pubmed: 29373477
J Pediatr. 2019 Jan;204:177-182.e1
pubmed: 30297292
Am J Respir Crit Care Med. 2003 Mar 1;167(5):695-701
pubmed: 12433670
Lancet. 2015 Jan 31;385(9966):430-40
pubmed: 25280870
Pediatrics. 2019 Jul;144(1):
pubmed: 31167938
JAMA Pediatr. 2019 Apr 1;173(4):342-351
pubmed: 30776077
Stat Med. 2019 Mar 30;38(7):1276-1296
pubmed: 30357870
Medicine (Baltimore). 2019 Jan;98(2):e13989
pubmed: 30633182
Pediatrics. 2011 Sep;128(3):595-610
pubmed: 21873693
Stat Med. 2016 Jan 30;35(2):214-26
pubmed: 26553135
Lancet Infect Dis. 2019 Apr;19(4):382-391
pubmed: 30827808

Auteurs

Nienke N Hagedoorn (NN)

General Paediatrics, Erasmus MC Sophia Children's Hospital, Rotterdam, Zuid-Holland, The Netherlands.

Dorine Borensztajn (D)

General Paediatrics, Erasmus MC Sophia Children's Hospital, Rotterdam, Zuid-Holland, The Netherlands.

Ruud Gerard Nijman (RG)

Section of Paediatric Infectious Diseases, Imperial College London, London, UK.

Daan Nieboer (D)

Public Health, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands.

Jethro Adam Herberg (JA)

Section of Paediatric Infectious Diseases, Imperial College London, London, UK.

Anda Balode (A)

Paediatrics, Children clinical university hospital, Rigas Stradinas Universitate, Riga, Latvia.

Ulrich von Both (U)

Division of Paediatric Infectious Diseases, Dr von Haunersches Kinderspital Kinderklinik und Kinderpoliklinik der Ludwig Maximilian Universitat Munchen, Munchen, Bayern, Germany.
Partner site Munich, German Centre for Infection Research, Braunschweig, Niedersachsen, Germany.

Enitan Carrol (E)

Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, Merseyside, UK.
Alder Hey Children's NHS Foundation Trust, Liverpool, Merseyside, UK.

Irini Eleftheriou (I)

Second Department of Paediatrics, P & A Kyriakou Children's Hospital, National and Kapodistrian University of Athens, Athinon, Greece.

Marieke Emonts (M)

Paediatric Immunology, Infectious Diseases & Allergy, Great North Children's Hospital, Newcastle upon Tyne, UK.
Newcastle upon Tyne Hospital NHS Trust and Newcastle University, NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne, Tyne and Wear, UK.

Michiel van der Flier (M)

Paediatric Infectious Diseases and Immunology, Amalia Children's Hospital, Radboudumc, Nijmegen, Gelderland, The Netherlands.
Wilhelmina Children's Hospital, Paediatric Infectious Diseases and Immunology, UMC Utrecht, Utrecht, The Netherlands.

Ronald de Groot (R)

Paediatric Infectious Diseases and Immunology, Amalia Children's Hospital, Radboudumc, Nijmegen, Gelderland, The Netherlands.

Benno Kohlmaier (B)

Department of General Paediatrics, Medical University of Graz, Graz, Steiermark, Austria.

Emma Lim (E)

Paediatric Immunology, Infectious Diseases & Allergy, Great North Children's Hospital, Newcastle upon Tyne, UK.
Newcastle upon Tyne Hospital NHS Trust and Newcastle University, NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne, Tyne and Wear, UK.

Ian Maconochie (I)

Paediatric Emergency Medicine, Imperial College Healthcare NHS Trust, London, UK.

Federico Martinón-Torres (F)

Genetics, Vaccines, Infections and Paediatrics Research group (GENVIP), Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain.

Marko Pokorn (M)

Department of Infectious Diseases and Faculty of Medicine, Ljubljanski Univerzitetni klinicni center, Ljubljana, Slovenia.

Franc Strle (F)

Department of Infectious Diseases and Faculty of Medicine, Ljubljanski Univerzitetni klinicni center, Ljubljana, Slovenia.

Maria Tsolia (M)

Second Department of Paediatrics, P & A Kyriakou Children's Hospital, National and Kapodistrian University of Athens, Athinon, Greece.

Dace Zavadska (D)

Paediatrics, Children clinical university hospital, Rigas Stradinas Universitate, Riga, Latvia.

Werner Zenz (W)

Department of General Paediatrics, Medical University of Graz, Graz, Steiermark, Austria.

Michael Levin (M)

Section of Paediatric Infectious Diseases, Imperial College London, London, UK.

Clementien Vermont (C)

Department of Paediatric Infectious Diseases and Immunology, Erasmus MC Sophia Children's Hospital, Rotterdam, Nederland, The Netherlands.

Henriette A Moll (HA)

General Paediatrics, Erasmus MC Sophia Children's Hospital, Rotterdam, Zuid-Holland, The Netherlands h.a.moll@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH